LianBio Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
LianBio (LIANY) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.71 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2023-03-28
- LianBio share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.71, a 58.50% decline from fiscal 2021.
- LianBio share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $4.12.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|
| 2022-12-31 | $1.71 10-K · filed 2023-03-28 | |
| 2021-12-31 | $4.12 10-K · filed 2022-03-31 | |
| 2021-09-30 | $4.06 10-Q/A · filed 2022-01-10 |